BiotechTube
CircNova

CircNova

Cambridge, United States· Est.
circnova.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $3.2M

Overview

CircNova is a private, pre-clinical biotech firm founded in 2020, combining artificial intelligence and circular RNA biology to discover novel therapeutics. Its core technology, the AI NovaEngine, is claimed to be the world's first deep-learning platform capable of predicting circRNA 3D structures, aiming to accelerate drug design for challenging targets. The company, with dual locations in Detroit, Michigan and Cambridge, Massachusetts, is led by a team with experience in biotech and AI, and has secured early-stage investment from entities like Michigan Rise.

Oncology

Technology Platform

AI NovaEngine™: A deep-learning platform claimed to be the world's first to predict the 3D structure of circular RNAs (circRNAs), enabling generative design and analysis for therapeutic development.

Funding History

1
Total raised:$3.2M
Seed$3.2M

Opportunities

The large 'undruggable' proteome and growing RNA therapeutics market present a significant addressable opportunity.
CircNova's AI-first approach to designing stable circRNA molecules could provide a first-mover advantage in a nascent but promising modality, attracting partnership interest from larger pharma.

Risk Factors

High technical risk associated with validating AI-predicted circRNA structures and their therapeutic utility in vivo.
The company is pre-revenue and faces financing risk, alongside competition from well-funded entities in both AI-driven drug discovery and RNA therapeutics.

Competitive Landscape

CircNova competes with other AI-driven biotechs (e.g., Recursion, Exscientia) and circular RNA specialists (e.g., Orna Therapeutics, Laronde, CircBio). Its differentiation lies in the specific focus on AI for circRNA 3D structure prediction, a niche but critical capability within the broader field.

More companies in RNA Therapeutics (non-mRNA) →More companies in United States →